GH Research (GHRS) Long-Term Investments (2021 - 2025)
GH Research (GHRS) posted quarterly Long-Term Investments of $34.5 million for Q4 2025, up 3.47% year-over-year from $33.3 million in Q4 2024, and down 11.31% quarter-over-quarter from $38.9 million in Q3 2025.
Analysis
GH Research (GHRS) Long-Term Investments (2021 - 2025) Analysis & Trends
GH Research's Long-Term Investments history runs 5 years deep, the most recent figure standing at $34.5 million for Q4 2025.
- In Q4 2025, Long-Term Investments rose 3.47% year-over-year to $34.5 million; the TTM figure through Dec 2025 stood at $34.5 million (up 3.47% YoY), while the FY2025 annual figure was $34.5 million, up 3.47% from the prior year.
- Long-Term Investments for Q4 2025 stood at $34.5 million, down from $38.9 million in the prior quarter.
- The five-year high for Long-Term Investments was $122.1 million in Q4 2021, with the low at $33.3 million in Q4 2024.
- The 5-year median for Long-Term Investments is $54.7 million (2024), against an average of $58.8 million.
- The sharpest annual moves came in 2024 and 2025: Long-Term Investments plunged 45.54% in 2024, then advanced 3.47% in 2025.
- GH Research's Long-Term Investments stood at $122.1 million in 2021, then dropped by 29.78% to $85.7 million in 2022, then slipped by 28.68% to $61.1 million in 2023, then sank by 45.54% to $33.3 million in 2024, then gained by 3.47% to $34.5 million in 2025.
- Business Quant data shows GHRS's Long-Term Investments at $34.5 million in Q4 2025, $38.9 million in Q3 2025, and $37.7 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -4.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 1.77 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.17 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 372.10 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | GH Research | 1.72 Bn | 1.36 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 134.24 Mn |
| Dec 31, 2024 | 126.77 Mn |
| Dec 31, 2023 | 125.87 Mn |
| Dec 31, 2022 | 123.66 Mn |
| Dec 31, 2021 | 122.08 Mn |